ClinicalTrials.gg
Active, not recruitingNCT05868967Updated May 22, 2023

A Clinical Study to Investigate the Mass Balance and Biotransformation of [14C]DWP14012 in Healthy Chinese Male Subjects

A Phase 1 interventional study of [14C]DWP14012 in Phase 1 Study, Healthy Volunteers, sponsored by Daewoong Pharmaceutical Co. LTD.. Active, not recruiting at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-22.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by May 2023, 3 years 5 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The purpose of this study is to investigate the Mass Balance and Biotransformation of [14C]DWP14012 in Healthy Chinese Male Subjects

Read the detailed description

This study is a single-center, single-dose, non-randomized, open-label design with two parts. Each subject will receive a single oral dose of [14C]DWP14012 suspension (containing approximately 40 mg/80 μCi [14C]DWP14012) under the fasting conditions

02

Conditions studied

  • Phase 1 Study, Healthy Volunteers
03

In context

Lead sponsor

Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects aged 18 to 45 years (including boundary values);
  2. Body weight ≥ 50.0 kg and (BMI) between 19.0 and 26.0 kg/m2 (including boundary values);
  3. Subjects must give to this study before the study and voluntarily sign a written informed consent form;
  4. Have no plan for fertility/sperm donation during the study and within 1 year after completion of the study, and take strict measures with their spouses (see Appendix 3 for details);
  5. Have good hygiene habits, and are able to communicate well with the investigator and complete the study in accordance with the study regulations.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with an allergic constitution, including those with a history of drug allergy or allergic reactions and are known to be allergic to this product or other P-CABs, PPIs or other drugs (e.g., aspirin and antibiotics); and those who are allergic to any food ingredients or have special requirements for diet and unable to take the unified diet;
  2. Subjects with abnormalities or medical history of hepatic, renal, gastrointestinal, neurological, respiratory, endocrine, hematological, oncological, cardiovascular, urological, or psychiatric disorders;
  3. Subjects with abnormal and clinically significant results of vital signs, physical examination, laboratory tests (hematology, blood chemistry, urinalysis, coagulation function, thyroid functions (FT3, FT4, TSH), stool routine + occult blood), 12-lead , abdominal B-ultrasound (hepatobiliary, pancreas, spleen and kidney) as judged by the investigator;
  4. Subjects who are positive for any one of the surface antigen, antibody, treponema pallidum antibody, and antigen/antibody combination test (primary screening);
  5. Subjects with any medical condition that, in the opinion of the investigator, may increase the risk during the subject's participation in this study (especially a history of esophageal or gastrointestinal ulcers), may interfere with drug absorption, distribution, metabolism or excretion, or may impair protocol compliance;
  6. Subjects with frequent alcohol consumption within 6 months prior to screening, i.e., more than 14 units of alcohol per week (1 unit = 285 mL of beer or 25 mL of spirits containing 40% alcohol or 100 mL of wine); or alcoholics; or those with a positive alcohol breath test at screening and baseline admission;
  7. Subjects who have smoked more than 5 cigarettes per day or habitually used nicotine-containing products within 3 months before screening and are unable to withdraw during the study;
  8. Subjects who have used soft drugs (e.g., cannabis) within 3 months before screening or hard drugs (e.g., cocaine, amphetamines, phencyclidine, etc.) within 1 year before screening; or have a history of drug abuse; or have a positive urine drug test at screening and baseline admission;
  9. Subjects who have taken any product or participated in any clinical trial of drugs within 3 months prior to screening;
  10. Subjects who have participated in blood donation within 3 months prior to screening with a total blood donation of ≥ 400 mL or total blood loss of ≥ 400 mL, or who have participated in blood donation within one month prior to screening with a total blood donation of ≥ 200 mL or total blood loss of ≥ 200 mL; or who have received blood transfusion; or who plan to donate blood within 1 month after the end of this study;
  11. Subjects who have used any medication that alters liver enzyme activity within 4 weeks prior to dosing (see Appendix 1 for details);
  12. Subjects who have used any prescription or over-the-counter drugs, any vitamin products, health care drugs or Chinese herbal medicines within 14 days prior to dosing;
  13. Subjects who have habitual consumption of grapefruit juice or excessive amounts of tea, coffee and/or caffeine-containing beverages, and are unable to withdraw during the study;
  14. Subjects with a history of fear of needles and hemophobia, difficulty in blood collection or intolerance to venipuncture blood collection; radiopharmaceutical labeling studies;
  15. Subjects whose work requires long-term exposure to radioactive conditions; or who have significant radioactive exposure (≥ 2 chest/ abdominal CTs, or ≥ 3 other types of X-rays) within 1 year prior to screening; or who have participated in radiopharmaceutical labeling studies;
  16. Subjects with other factors that are not suitable for participation in this study as judged by the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    [14C]DWP14012

    Type: \[14C\]DWP14012 suspension containing 40 mg/80 μCi Dosage: orally take the suspension

    Drug: [14C]DWP14012

Interventions

  • Each subject will receive a single oral dose of \[14C\]DWP14012 suspension (containing approximately 40 mg/80 μCi \[14C\]DWP14012) under fasting conditions.

06

What researchers measure

Primary outcomes

  1. Tmax

    Time to peak Concentration

    Time frame: Up to 168hours(approx) from administration

  2. Cmax

    Maximum Concentration

    Time frame: Up to 168hours(approx) from administration

  3. AUC0-t

    Area under the plasma concentraion-time curve

    Time frame: Up to 168hours(approx) from administration

  4. AUC0-∞

    Area under the curve from time 0 extrapolated to infinite time

    Time frame: Up to 168hours(approx) from administration

  5. t1/2

    Elimination Phase Half-life

    Time frame: Up to 168hours(approx) from administration

  6. MRT

    Mean Residence Time

    Time frame: Up to 168hours(approx) from administration

  7. CL/F

    apparent oral clearnace

    Time frame: Up to 168hours(approx) from administration

  8. Vd/F

    apparent oral volume of distribution

    Time frame: Up to 168hours(approx) from administration

  9. Ratio of total radioactivity in whole blood/plasma

    Total measured radioactivity content of urine and fecal samples collected at each sampling interval

    Time frame: Up to 168hours(approx) from administration

  10. Cumulative recovery of total radioactive substances

    Measurement of cumulative recovery ratio in urine or/and feces to meet the criteria for termination

    Time frame: Up to 168hours(approx) from administration

Secondary outcomes

  1. To observe the safety of [14C]DWP14012

    Adverse events, serious adverse events etc.

    Time frame: Up to study completion, approximately up to 2000 hours

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2023 (actual). Primary completion is estimated for May 2023, 3 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2023
First posted
May 22, 2023
StartActual
Feb 27, 2023
Primary completionEst.
May 31, 2023
CompletionEst.
Oct 31, 2023
Last update
May 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05868967
Collaborators
Shanghai Haini Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
May 22, 2023
Start date
Feb 27, 2023
Primary completion
May 31, 2023 (estimated)
Completion
Oct 31, 2023 (estimated)
Last update
May 22, 2023

Study contacts

Fang Hou
principal investigator · Beijing GoBroad Boren Hospital
Wel Tan
principal investigator · Beijing GoBroad Boren Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fexuprazan

Start the discussion